{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,10]],"date-time":"2026-01-10T08:38:27Z","timestamp":1768034307124,"version":"3.49.0"},"reference-count":53,"publisher":"Springer Science and Business Media LLC","issue":"1","content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Trials"],"DOI":"10.1186\/1745-6215-15-160","type":"journal-article","created":{"date-parts":[[2014,5,8]],"date-time":"2014-05-08T01:03:20Z","timestamp":1399511000000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":29,"title":["Benefits of Aldosterone Receptor Antagonism in Chronic Kidney Disease (BARACK D) trial\u2013a multi-centre, prospective, randomised, open, blinded end-point, 36-month study of 2,616 patients within primary care with stage 3b chronic kidney disease to compare the efficacy of spironolactone 25\u00a0mg once daily in addition to routine care on mortality and cardiovascular outcomes versus routine care alone: study protocol for a randomized controlled trial"],"prefix":"10.1186","volume":"15","author":[{"given":"Nathan R","family":"Hill","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daniel","family":"Lasserson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ben","family":"Thompson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rafael","family":"Perera-Salazar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jane","family":"Wolstenholme","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peter","family":"Bower","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thomas","family":"Blakeman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David","family":"Fitzmaurice","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paul","family":"Little","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gene","family":"Feder","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nadeem","family":"Qureshi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maarten","family":"Taal","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jonathan","family":"Townend","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Charles","family":"Ferro","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Richard","family":"McManus","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"FD Richard","family":"Hobbs","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2014,5,8]]},"reference":[{"issue":"3","key":"2040_CR1","doi-asserted-by":"publisher","first-page":"c213","DOI":"10.1159\/000320341","volume":"117","author":"S de Lusignan","year":"2011","unstructured":"de Lusignan S, Tomson C, Harris K, van Vlymen J, Gallagher H: Creatinine fluctuation has a greater effect than the formula to estimate glomerular filtration rate on the prevalence of chronic kidney disease. Nephron Clin Pract. 2011, 117 (3): c213-c224. 10.1159\/000320341.","journal-title":"Nephron Clin Pract"},{"key":"2040_CR2","doi-asserted-by":"publisher","first-page":"c107","DOI":"10.1159\/000337124","volume":"120","author":"S de Lusignan","year":"2012","unstructured":"de Lusignan S, Tomson C, Harris K, van Vlymen J, Gallagher H: UK Prevalence of chronic kidney disease for the adult population is 6.76% based on two creatinine readings [Erratum]. Nephron Clin Pract. 2012, 120: c107-10.1159\/000337124.","journal-title":"Nephron Clin Pract"},{"issue":"9889","key":"2040_CR3","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1016\/S0140-6736(13)60595-4","volume":"382","author":"RT Gansevoort","year":"2013","unstructured":"Gansevoort RT, Correa-Rotter R, Hemmelgarn BR, Jafar TH, Heerspink HJ, Mann JF, Matsushita K, Wen CP: Chronic kidney disease and cardiovascular risk: epidemiology, mechanisms, and prevention. Lancet. 2013, 382 (9889): 339-352. 10.1016\/S0140-6736(13)60595-4.","journal-title":"Lancet"},{"issue":"17","key":"2040_CR4","doi-asserted-by":"publisher","first-page":"2038","DOI":"10.1001\/jama.298.17.2038","volume":"298","author":"J Coresh","year":"2007","unstructured":"Coresh J, Selvin E, Stevens LA, Manzi J, Kusek JW, Eggers P, Van Lente F, Levey AS: Prevalence of chronic kidney disease in the United States. JAMA. 2007, 298 (17): 2038-2047. 10.1001\/jama.298.17.2038.","journal-title":"JAMA"},{"key":"2040_CR5","volume-title":"Evaluation, Classification, and Stratification","author":"KDOQI KDOQI. Chronic Kidney Disease","year":"2002","unstructured":"KDOQI KDOQI. Chronic Kidney Disease: Evaluation, Classification, and Stratification. 2002, [http:\/\/www.kidney.org\/professionals\/kdoqi\/guidelines_commentaries.cfm]"},{"key":"2040_CR6","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1186\/1748-5908-4-39","volume":"4","author":"S de Lusignan","year":"2009","unstructured":"de Lusignan S, Gallagher H, Chan T, Thomas N, van Vlymen J, Nation M, Jain N, Tahir A, du Bois E, Crinson I, Hague N, Reid F, Harris K: The QICKD study protocol: a cluster randomised trial to compare quality improvement interventions to lower systolic BP in chronic kidney disease (CKD) in primary care. Implementation Sci. 2009, 4: 39-10.1186\/1748-5908-4-39.","journal-title":"Implementation Sci"},{"issue":"6","key":"2040_CR7","doi-asserted-by":"publisher","first-page":"461","DOI":"10.7326\/0003-4819-130-6-199903160-00002","volume":"130","author":"AS Levey","year":"1999","unstructured":"Levey AS, Bosch JP, Lewis JB, Greene T, Rogers N, Roth D: A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of Diet in Renal Disease Study Group. Ann Intern Med. 1999, 130 (6): 461-470. 10.7326\/0003-4819-130-6-199903160-00002.","journal-title":"Ann Intern Med"},{"issue":"7577","key":"2040_CR8","doi-asserted-by":"publisher","first-page":"1047","DOI":"10.1136\/bmj.39001.657755.BE","volume":"333","author":"SI Hallan","year":"2006","unstructured":"Hallan SI, Dahl K, Oien CM, Grootendorst DC, Aasberg A, Holmen J, Dekker FW: Screening strategies for chronic kidney disease in the general population: follow-up of cross sectional health survey. BMJ. 2006, 333 (7577): 1047-10.1136\/bmj.39001.657755.BE.","journal-title":"BMJ"},{"issue":"1","key":"2040_CR9","doi-asserted-by":"publisher","first-page":"180","DOI":"10.1681\/ASN.2004070539","volume":"16","author":"J Coresh","year":"2005","unstructured":"Coresh J, Byrd-Holt D, Astor BC, Briggs JP, Eggers PW, Lacher DA, Hostetter TH: Chronic kidney disease awareness, prevalence, and trends among U.S. adults, 1999 to 2000. J Am Soc Nephrol. 2005, 16 (1): 180-188.","journal-title":"J Am Soc Nephrol"},{"issue":"1","key":"2040_CR10","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1053\/ajkd.2003.50007","volume":"41","author":"J Coresh","year":"2003","unstructured":"Coresh J, Astor BC, Greene T, Eknoyan G, Levey AS: Prevalence of chronic kidney disease and decreased kidney function in the adult US population: Third National Health and Nutrition Examination Survey. Am J Kidney Dis. 2003, 41 (1): 1-12. 10.1053\/ajkd.2003.50007.","journal-title":"Am J Kidney Dis"},{"issue":"6","key":"2040_CR11","doi-asserted-by":"publisher","first-page":"659","DOI":"10.1001\/archinte.164.6.659","volume":"164","author":"DS Keith","year":"2004","unstructured":"Keith DS, Nichols GA, Gullion CM, Brown JB, Smith DH: Longitudinal follow-up and outcomes among a population with chronic kidney disease in a large managed care organization. Arch Intern Med. 2004, 164 (6): 659-663. 10.1001\/archinte.164.6.659.","journal-title":"Arch Intern Med"},{"issue":"13","key":"2040_CR12","doi-asserted-by":"publisher","first-page":"1296","DOI":"10.1056\/NEJMoa041031","volume":"351","author":"AS Go","year":"2004","unstructured":"Go AS, Chertow GM, Fan D, McCulloch CE, Hsu CY: Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. N Engl J Med. 2004, 351 (13): 1296-1305. 10.1056\/NEJMoa041031.","journal-title":"N Engl J Med"},{"issue":"9731","key":"2040_CR13","doi-asserted-by":"publisher","first-page":"2073","DOI":"10.1016\/S0140-6736(10)60674-5","volume":"375","author":"C Chronic Kidney Disease Prognosis","year":"2010","unstructured":"Chronic Kidney Disease Prognosis C, Matsushita K, van der Velde M, Astor BC, Woodward M, Levey AS, de Jong PE, Coresh J, Gansevoort RT: Association of estimated glomerular filtration rate and albuminuria with all-cause and cardiovascular mortality in general population cohorts: a collaborative meta-analysis. Lancet. 2010, 375 (9731): 2073-2081.","journal-title":"Lancet"},{"issue":"2","key":"2040_CR14","doi-asserted-by":"publisher","first-page":"610","DOI":"10.1046\/j.1523-1755.2003.00109.x","volume":"64","author":"JL Abramson","year":"2003","unstructured":"Abramson JL, Jurkovitz CT, Vaccarino V, Weintraub WS, McClellan W: Chronic kidney disease, anemia, and incident stroke in a middle-aged, community-based population: the ARIC Study. Kidney Int. 2003, 64 (2): 610-615. 10.1046\/j.1523-1755.2003.00109.x.","journal-title":"Kidney Int"},{"issue":"4","key":"2040_CR15","doi-asserted-by":"publisher","first-page":"478","DOI":"10.1093\/eurheartj\/ehl455","volume":"28","author":"W Van Biesen","year":"2007","unstructured":"Van Biesen W, De Bacquer D, Verbeke F, Delanghe J, Lameire N, Vanholder R: The glomerular filtration rate in an apparently healthy population and its relation with cardiovascular mortality during 10\u00a0years. Eur Heart J. 2007, 28 (4): 478-483. 10.1093\/eurheartj\/ehl455.","journal-title":"Eur Heart J"},{"issue":"2","key":"2040_CR16","doi-asserted-by":"publisher","first-page":"e000308","DOI":"10.1136\/bmjopen-2011-000308","volume":"1","author":"CA O'Callaghan","year":"2011","unstructured":"O'Callaghan CA, Shine B, Lasserson DS: Chronic kidney disease: a large-scale population-based study of the effects of introducing the CKD-EPI formula for eGFR reporting. BMJ Open. 2011, 1 (2): e000308-","journal-title":"BMJ Open"},{"issue":"5","key":"2040_CR17","doi-asserted-by":"publisher","first-page":"805","DOI":"10.2215\/CJN.07761109","volume":"5","author":"RN Foley","year":"2010","unstructured":"Foley RN, Curtis BM, Randell EW, Parfrey PS: Left ventricular hypertrophy in new hemodialysis patients without symptomatic cardiac disease. Clin J Am Soc Nephrol. 2010, 5 (5): 805-813. 10.2215\/CJN.07761109.","journal-title":"Clin J Am Soc Nephrol"},{"issue":"2","key":"2040_CR18","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1681\/ASN.2004030203","volume":"16","author":"RN Foley","year":"2005","unstructured":"Foley RN, Murray AM, Li S, Herzog CA, McBean AM, Eggers PW, Collins AJ: Chronic kidney disease and the risk for cardiovascular disease, renal replacement, and death in the United States Medicare population, 1998 to 1999. J Am Soc Nephrol. 2005, 16 (2): 489-495. 10.1681\/ASN.2004030203.","journal-title":"J Am Soc Nephrol"},{"key":"2040_CR19","doi-asserted-by":"publisher","first-page":"S24","DOI":"10.1046\/j.1523-1755.64.s87.5.x","volume":"87","author":"AJ Collins","year":"2003","unstructured":"Collins AJ, Li S, Gilbertson DT, Liu J, Chen SC, Herzog CA: Chronic kidney disease and cardiovascular disease in the Medicare population. Kidney Int Suppl. 2003, 87: S24-S31.","journal-title":"Kidney Int Suppl"},{"issue":"2","key":"2040_CR20","doi-asserted-by":"publisher","first-page":"529","DOI":"10.1681\/ASN.2004080656","volume":"16","author":"P Muntner","year":"2005","unstructured":"Muntner P, He J, Astor BC, Folsom AR, Coresh J: Traditional and nontraditional risk factors predict coronary heart disease in chronic kidney disease: results from the atherosclerosis risk in communities study. J Am Soc Nephrol. 2005, 16 (2): 529-538. 10.1681\/ASN.2004080656.","journal-title":"J Am Soc Nephrol"},{"issue":"5","key":"2040_CR21","doi-asserted-by":"publisher","first-page":"1834","DOI":"10.1046\/j.1523-1755.2001.0590051834.x","volume":"59","author":"JJ Mourad","year":"2001","unstructured":"Mourad JJ, Pannier B, Blacher J, Rudnichi A, Benetos A, London GM, Safar ME: Creatinine clearance, pulse wave velocity, carotid compliance and essential hypertension. Kidney Int. 2001, 59 (5): 1834-1841. 10.1046\/j.1523-1755.2001.0590051834.x.","journal-title":"Kidney Int"},{"issue":"8","key":"2040_CR22","doi-asserted-by":"publisher","first-page":"1038","DOI":"10.1136\/hrt.2007.137539","volume":"94","author":"NC Edwards","year":"2008","unstructured":"Edwards NC, Ferro CJ, Townend JN, Steeds RP: Aortic distensibility and arterial-ventricular coupling in early chronic kidney disease: a pattern resembling heart failure with preserved ejection fraction. Heart. 2008, 94 (8): 1038-1043. 10.1136\/hrt.2007.137539.","journal-title":"Heart"},{"key":"2040_CR23","volume-title":"Draft Guideline","author":"NICE NIfCE. Chronic Kidney Disease (Update)","year":"2014","unstructured":"NICE NIfCE. Chronic Kidney Disease (Update): Draft Guideline. 2014, [http:\/\/guidance.nice.org.uk\/CG\/WaveR\/130\/Consultation\/Latest]"},{"issue":"9784","key":"2040_CR24","doi-asserted-by":"publisher","first-page":"2181","DOI":"10.1016\/S0140-6736(11)60739-3","volume":"377","author":"C Baigent","year":"2011","unstructured":"Baigent C, Landray MJ, Reith C, Emberson J, Wheeler DC, Tomson C, Wanner C, Krane V, Cass A, Craig J, Neal B, Jiang L, Hooi LS, Levin A, Agodoa L, Gaziano M, Kasiske B, Walker R, Massy ZA, Feldt-Rasmussen B, Krairittichai U, Ophascharoensuk V, Fellstr\u00f6m B, Holdaas H, Tesar V, Wiecek A, Grobbee D, de Zeeuw D, Gr\u00f6nhagen-Riska C, Dasgupta T, SHARP Investigators: The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (Study of Heart and Renal Protection): a randomised placebo-controlled trial. Lancet. 2011, 377 (9784): 2181-2192. 10.1016\/S0140-6736(11)60739-3.","journal-title":"Lancet"},{"issue":"5","key":"2040_CR25","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1056\/NEJM199108013250501","volume":"325","author":"SOLVD Investigators","year":"1991","unstructured":"Investigators SOLVD: Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. The SOLVD Investigators. N Engl J Med. 1991, 325 (5): 293-302.","journal-title":"N Engl J Med"},{"issue":"7","key":"2040_CR26","doi-asserted-by":"publisher","first-page":"2034","DOI":"10.1681\/ASN.2005101085","volume":"17","author":"M Tonelli","year":"2006","unstructured":"Tonelli M, Wiebe N, Culleton B, House A, Rabbat C, Fok M, McAlister F, Garg AX: Chronic kidney disease and mortality risk: a systematic review. J Am Soc Nephrol. 2006, 17 (7): 2034-2047. 10.1681\/ASN.2005101085.","journal-title":"J Am Soc Nephrol"},{"issue":"10","key":"2040_CR27","doi-asserted-by":"publisher","first-page":"1505","DOI":"10.1016\/j.amjcard.2010.07.018","volume":"106","author":"NC Edwards","year":"2010","unstructured":"Edwards NC, Ferro CJ, Kirkwood H, Chue CD, Young AA, Stewart PM, Steeds RP, Townend JN: Effect of spironolactone on left ventricular systolic and diastolic function in patients with early stage chronic kidney disease. Am J Cardiol. 2010, 106 (10): 1505-1511. 10.1016\/j.amjcard.2010.07.018.","journal-title":"Am J Cardiol"},{"issue":"6","key":"2040_CR28","doi-asserted-by":"publisher","first-page":"594","DOI":"10.1161\/01.CIR.101.6.594","volume":"101","author":"CA Farquharson","year":"2000","unstructured":"Farquharson CA, Struthers AD: Spironolactone increases nitric oxide bioactivity, improves endothelial vasodilator dysfunction, and suppresses vascular angiotensin I\/angiotensin II conversion in patients with chronic heart failure. Circulation. 2000, 101 (6): 594-597. 10.1161\/01.CIR.101.6.594.","journal-title":"Circulation"},{"issue":"8","key":"2040_CR29","doi-asserted-by":"publisher","first-page":"1380","DOI":"10.2215\/CJN.09421209","volume":"5","author":"A Vukusich","year":"2010","unstructured":"Vukusich A, Kunstmann S, Varela C, Gainza D, Bravo S, Sepulveda D, Cavada G, Michea L, Marusic ET: A randomized, double-blind, placebo-controlled trial of spironolactone on carotid intima-media thickness in nondiabetic hemodialysis patients. Clin J Am Soc Nephrol. 2010, 5 (8): 1380-1387. 10.2215\/CJN.09421209.","journal-title":"Clin J Am Soc Nephrol"},{"issue":"11","key":"2040_CR30","doi-asserted-by":"publisher","first-page":"679","DOI":"10.1038\/nrcardio.2009.175","volume":"6","author":"B Pitt","year":"2009","unstructured":"Pitt B: Pharmacotherapy: Cardiovascular effects of aldosterone blockade in CKD. Nat Rev Cardiol. 2009, 6 (11): 679-680. 10.1038\/nrcardio.2009.175.","journal-title":"Nat Rev Cardiol"},{"issue":"1","key":"2040_CR31","first-page":"46","volume":"26","author":"CA Herzog","year":"2011","unstructured":"Herzog CA: Kidney disease in cardiology. Nephrology, dialysis, transplantation: official publication of the European Dialysis and Transplant Association. Eur Renal Assoc. 2011, 26 (1): 46-50.","journal-title":"Eur Renal Assoc"},{"issue":"4","key":"2040_CR32","doi-asserted-by":"publisher","first-page":"839","DOI":"10.1161\/01.HYP.0000259805.18468.8c","volume":"49","author":"N Chapman","year":"2007","unstructured":"Chapman N, Dobson J, Wilson S, Dahl\u00f6f B, Sever PS, Wedel H, Poulter NR, Anglo-Scandinavian Cardiac Outcomes Trial Investigators: Effect of spironolactone on blood pressure in subjects with resistant hypertension. Hypertension. 2007, 49 (4): 839-845. 10.1161\/01.HYP.0000259805.18468.8c.","journal-title":"Hypertension"},{"issue":"9502","key":"2040_CR33","doi-asserted-by":"publisher","first-page":"2026","DOI":"10.1016\/S0140-6736(05)67814-2","volume":"366","author":"JP Casas","year":"2005","unstructured":"Casas JP, Chua W, Loukogeorgakis S, Vallance P, Smeeth L, Hingorani AD, MacAllister RJ: Effect of inhibitors of the renin-angiotensin system and other antihypertensive drugs on renal outcomes: systematic review and meta-analysis. Lancet. 2005, 366 (9502): 2026-2033. 10.1016\/S0140-6736(05)67814-2.","journal-title":"Lancet"},{"issue":"3","key":"2040_CR34","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1056\/NEJM200001203420301","volume":"342","author":"S Yusuf","year":"2000","unstructured":"Yusuf S, Sleight P, Pogue J, Bosch J, Davies R, Dagenais G: Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. N Engl J Med. 2000, 342 (3): 145-153.","journal-title":"N Engl J Med"},{"issue":"2 Suppl 1","key":"2040_CR35","first-page":"S1","volume":"39","author":"National Kidney Foundation N","year":"2002","unstructured":"National Kidney Foundation N: K\/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Am J Kidney Dis. 2002, 39 (2 Suppl 1): S1-S266.","journal-title":"Am J Kidney Dis"},{"key":"2040_CR36","volume-title":"Diagnosis and Management of Chronic Kidney Disease","author":"SIGN","year":"2008","unstructured":"SIGN: Diagnosis and Management of Chronic Kidney Disease. 2008, [http:\/\/www.sign.ac.uk\/guidelines\/fulltext\/103\/]"},{"key":"2040_CR37","volume-title":"CG73 Chronic Kidney Disease: Full Guideline","author":"NICE NIfCE","year":"2008","unstructured":"NICE NIfCE: CG73 Chronic Kidney Disease: Full Guideline. 2008, [http:\/\/guidance.nice.org.uk\/CG73\/Guidance\/pdf\/English]"},{"issue":"19","key":"2040_CR38","doi-asserted-by":"publisher","first-page":"2512","DOI":"10.1161\/01.CIR.0000071081.35693.9A","volume":"107","author":"NJ Brown","year":"2003","unstructured":"Brown NJ: Eplerenone: cardiovascular protection. Circulation. 2003, 107 (19): 2512-2518. 10.1161\/01.CIR.0000071081.35693.9A.","journal-title":"Circulation"},{"issue":"1\u20132","key":"2040_CR39","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1016\/j.mce.2008.10.029","volume":"301","author":"JW Funder","year":"2009","unstructured":"Funder JW, Mihailidou AS: Aldosterone and mineralocorticoid receptors: Clinical studies and basic biology. Mol Cell Endocrinol. 2009, 301 (1\u20132): 2-6.","journal-title":"Mol Cell Endocrinol"},{"issue":"5 Suppl","key":"2040_CR40","doi-asserted-by":"publisher","first-page":"S2","DOI":"10.1067\/mhj.2002.129969","volume":"144","author":"AD Struthers","year":"2002","unstructured":"Struthers AD: Aldosterone: cardiovascular assault. Am Heart J. 2002, 144 (5 Suppl): S2-S7.","journal-title":"Am Heart J"},{"issue":"6 Pt 1","key":"2040_CR41","doi-asserted-by":"publisher","first-page":"971","DOI":"10.1161\/01.HYP.26.6.971","volume":"26","author":"V Robert","year":"1995","unstructured":"Robert V, Silvestre JS, Charlemagne D, Sabri A, Trouv\u00e9 P, Wassef M, Swynghedauw B, Delcayre C: Biological determinants of aldosterone-induced cardiac fibrosis in rats. Hypertension. 1995, 26 (6 Pt 1): 971-978.","journal-title":"Hypertension"},{"issue":"5","key":"2040_CR42","doi-asserted-by":"publisher","first-page":"911","DOI":"10.1161\/HYPERTENSIONAHA.107.095448","volume":"50","author":"C Catena","year":"2007","unstructured":"Catena C, Colussi G, Lapenna R, Nadalini E, Chiuch A, Gianfagna P, Sechi LA: Long-term cardiac effects of adrenalectomy or mineralocorticoid antagonists in patients with primary aldosteronism. Hypertension. 2007, 50 (5): 911-918. 10.1161\/HYPERTENSIONAHA.107.095448.","journal-title":"Hypertension"},{"issue":"8","key":"2040_CR43","doi-asserted-by":"publisher","first-page":"1243","DOI":"10.1016\/j.jacc.2005.01.015","volume":"45","author":"P Milliez","year":"2005","unstructured":"Milliez P, Girerd X, Plouin PF, Blacher J, Safar ME, Mourad JJ: Evidence for an increased rate of cardiovascular events in patients with primary aldosteronism. J Am Coll Cardiol. 2005, 45 (8): 1243-1248. 10.1016\/j.jacc.2005.01.015.","journal-title":"J Am Coll Cardiol"},{"issue":"20","key":"2040_CR44","doi-asserted-by":"publisher","first-page":"2489","DOI":"10.1093\/eurheartj\/ehn383","volume":"29","author":"BR Palmer","year":"2008","unstructured":"Palmer BR, Pilbrow AP, Frampton CM, Yandle TG, Skelton L, Nicholls MG, Richards AM: Plasma aldosterone levels during hospitalization are predictive of survival post-myocardial infarction. Eur Heart J. 2008, 29 (20): 2489-2496. 10.1093\/eurheartj\/ehn383.","journal-title":"Eur Heart J"},{"issue":"10","key":"2040_CR45","doi-asserted-by":"publisher","first-page":"1237","DOI":"10.1093\/eurheartj\/ehq019","volume":"31","author":"A Tomaschitz","year":"2010","unstructured":"Tomaschitz A, Pilz S, Ritz E, Meinitzer A, Boehm BO, M\u00e4rz W: Plasma aldosterone levels are associated with increased cardiovascular mortality: the Ludwigshafen Risk and Cardiovascular Health (LURIC) study. Eur Heart J. 2010, 31 (10): 1237-1247. 10.1093\/eurheartj\/ehq019.","journal-title":"Eur Heart J"},{"key":"2040_CR46","volume-title":"Cochrane Database Syst Rev","author":"SD Navaneethan","year":"2009","unstructured":"Navaneethan SD, Nigwekar SU, Sehgal AR, Strippoli GF: Aldosterone antagonists for preventing the progression of chronic kidney disease. Cochrane Database Syst Rev. 2009, 3: CD007004"},{"issue":"1","key":"2040_CR47","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1159\/000210553","volume":"114","author":"Y Matsumoto","year":"2009","unstructured":"Matsumoto Y, Kageyama S, Yakushigawa T, Arihara K, Sugiyama T, Mori Y, Sugiyama H, Ohmura H, Shio N: Long-term low-dose spironolactone therapy is safe in oligoanuric hemodialysis patients. Cardiology. 2009, 114 (1): 32-38. 10.1159\/000210553.","journal-title":"Cardiology"},{"issue":"3","key":"2040_CR48","doi-asserted-by":"publisher","first-page":"434","DOI":"10.1161\/01.HYP.38.3.434","volume":"38","author":"GM London","year":"2001","unstructured":"London GM, Blacher J, Pannier B, Guerin AP, Marchais SJ, Safar ME: Arterial wave reflections and survival in end-stage renal failure. Hypertension. 2001, 38 (3): 434-438. 10.1161\/01.HYP.38.3.434.","journal-title":"Hypertension"},{"key":"2040_CR49","volume-title":"British National Formulary","author":"Joint Formulary Committee","year":"2012","unstructured":"Joint Formulary Committee: British National Formulary. 2012, London: BMJ Publishing Group Ltd and Royal Pharmaceutical Society"},{"issue":"6","key":"2040_CR50","doi-asserted-by":"publisher","first-page":"2276","DOI":"10.1161\/STROKEAHA.108.192218","volume":"40","author":"JD Easton","year":"2009","unstructured":"Easton JD, Saver JL, Albers GW, Alberts MJ, Chaturvedi S, Feldmann E, Hatsukami TS, Higashida RT, Johnston SC, Kidwell CS, Lutsep HL, Miller E, Sacco RL, American Heart Association; American Stroke Association Stroke Council; Council on Cardiovascular Surgery and Anesthesia; Council on Cardiovascular Radiology and Intervention; Council on Cardiovascular Nursing; Interdisciplinary Council on Peripheral Vascular Disease: Definition and evaluation of transient ischemic attack: a scientific statement for healthcare professionals from the American Heart Association\/American Stroke Association Stroke Council; Council on Cardiovascular Surgery and Anesthesia; Council on Cardiovascular Radiology and Intervention; Council on Cardiovascular Nursing; and the Interdisciplinary Council on Peripheral Vascular Disease. The American Academy of Neurology affirms the value of this statement as an educational tool for neurologists. Stroke. 2009, 40 (6): 2276-2293. 10.1161\/STROKEAHA.108.192218.","journal-title":"Stroke"},{"issue":"22","key":"2040_CR51","doi-asserted-by":"publisher","first-page":"2700","DOI":"10.1161\/01.CIR.102.22.2700","volume":"102","author":"F Zannad","year":"2000","unstructured":"Zannad F, Alla F, Dousset B, Perez A, Pitt B: Limitation of excessive extracellular matrix turnover may contribute to survival benefit of spironolactone therapy in patients with congestive heart failure: insights from the randomized aldactone evaluation study (RALES). Rales Investigators. Circulation. 2000, 102 (22): 2700-2706. 10.1161\/01.CIR.102.22.2700.","journal-title":"Circulation"},{"key":"2040_CR52","volume-title":"NICE DSU Technical Support Document 14: Survival Analysis for Economic Evaluations Alongside Clinical Trials-Extrapolation with Patient Level Data","author":"NR Latimer","year":"2011","unstructured":"Latimer NR: NICE DSU Technical Support Document 14: Survival Analysis for Economic Evaluations Alongside Clinical Trials-Extrapolation with Patient Level Data. 2011, Sheffield: School of Health and Related Research, University of Sheffield"},{"key":"2040_CR53","doi-asserted-by":"publisher","first-page":"c869","DOI":"10.1136\/bmj.c869","volume":"340","author":"D Moher","year":"2010","unstructured":"Moher D, Hopewell S, Schulz KF, Montori V, G\u00f8tzsche PC, Devereaux PJ, Elbourne D, Egger M, Altman DG: CONSORT 2010 explanation and elaboration: updated guidelines for reporting parallel group randomised trials. BMJ. 2010, 340: c869-10.1136\/bmj.c869.","journal-title":"BMJ"}],"updated-by":[{"DOI":"10.1186\/s13063-022-06972-9","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2022,12,12]],"date-time":"2022-12-12T00:00:00Z","timestamp":1670803200000}}],"container-title":["Trials"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/1745-6215-15-160.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,12]],"date-time":"2022-12-12T07:12:11Z","timestamp":1670829131000},"score":1,"resource":{"primary":{"URL":"https:\/\/trialsjournal.biomedcentral.com\/articles\/10.1186\/1745-6215-15-160"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,5,8]]},"references-count":53,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2014,12]]}},"alternative-id":["2040"],"URL":"https:\/\/doi.org\/10.1186\/1745-6215-15-160","relation":{},"ISSN":["1745-6215"],"issn-type":[{"value":"1745-6215","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,5,8]]},"assertion":[{"value":"4 March 2014","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 April 2014","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 May 2014","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 December 2022","order":4,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":5,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A Correction to this paper has been published:","order":6,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"https:\/\/doi.org\/10.1186\/s13063-022-06972-9","URL":"https:\/\/doi.org\/10.1186\/s13063-022-06972-9","order":7,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}}],"article-number":"160"}}